GlassScriptPhysician profile
Laura E Sutaria
NPI 1750810354
$5,102.32
in general payments reported to CMS, 2019-2025
19 companies · $372 in 2025
The $372 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.62 · 2020: $138 · 2021: $425 · 2022: $3,503 · 2023: $334 · 2024: $316 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,023.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,022.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $3,066.72 | 2022 | |
| Medtronic, INC. | $651.41 | 2021-2025 | Onyx Frontier, Symplicity G3 |
| Novartis Pharmaceuticals Corporation | $301.99 | 2023-2025 | |
| Abbott Laboratories | $269.44 | 2022-2023 | Quadra Assura, Aveir, Na |
| Akcea Therapeutics, INC. | $105.65 | 2020 | |
| Alnylam Pharmaceuticals INC. | $90.95 | 2023 | Onpattro |
| Astrazeneca Pharmaceuticals LP | $59.63 | 2021-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.25 | 2025 | Jardiance |
| Pfizer INC. | $44.24 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $33.64 | 2025 | Eliquis |
| Irhythm Technologies, INC. | $32.41 | 2023 | Zio Xt Patch |
| Daiichi Sankyo INC. | $29.45 | 2025 | Injectafer |
| Abiomed | $24.67 | 2023 | Impella |
| Sobi, INC | $22.22 | 2021 | |
| Merck Sharp & Dohme LLC | $22.21 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $22.18 | 2025 | Repatha |
| Lexicon Pharmaceuticals, INC. | $18.51 | 2024 | |
| Boston Scientific Corporation | $13.83 | 2020 | |
| Amag Pharmaceuticals, INC. | $13.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Sutaria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.